Dexcom, Inc., headquartered in San Diego, California, is dedicated to helping people better manage their diabetes by providing exceptional continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. Our latest-generation CGM, the Dexcom G5â„˘ Mobile CGM System, is the first FDA-approved, fully mobile System for both adults and children 2 years and older. Patients can not only view their real-time glucose data via their smart device*, but also share it with loved ones without needing a receiver. Our CGM features customizable alerts and alarms to warn patients of highs and lows and how quickly they may be happening. We also offer Dexcom CLARITYâ„˘, an advanced reporting tool for users to identify their unique glucose patterns, while also discovering potential solutions to help them spend more time in their target range. For more information, visit www.dexcom.com.
*For a list of compatible devices, please visit www.dexcom.com/compatibility
Ever since we introduced the first commercial insulin in 1923, Lilly Diabetes has been a global leader in diabetes care. Today, Lilly continues to develop innovative products, programs, and resources to help people with type 1 diabetes. For the past twelve years, Lilly has been a proud platinum sponsor of the Friends for LifeÂ® Orlando conference.
Join us at our booth to see all the ways we support the type 1 community and how your family can get involved. You can learn more about the role we play in diabetes camps and scholarships for everyday heroes with type 1, discover awards that acknowledge success in diabetes management, and be inspired by the achievements of NASCAR driver Ryan Reed in managing his type 1 diabetes. Youâ€™ll also be able to check out our popular books for families managing type 1 diabetes. They've been created in collaboration with Disney and explore real-life issues that affect families just like yours. Be sure to pick up your free copy of each of the Lilly Diabetes and Disney storybooks, featuring Coco the monkey.
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures the t:slim X2â„˘ Insulin Pump, the next-generation color touchscreen pump, the t:flexÂ® Insulin Pump and the t:slim G4â„˘ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. Insulet's OmniPod® Insulin Management System is a revolutionary insulin infusion system â€“ the first and only tubeless system in the US â€“ that gives kids the freedom to be kids, and parents the peace of mind of continuous insulin therapy. The OmniPod® system packs all the functionality of today's "smart" insulin pumps in two discreet, easy-to-use wireless parts, featuring an integrated FreeStyle® blood glucose meter, and, best of all, no cumbersome tubing. The remote Personal Diabetes Manager (PDM) allows parents and caregivers additional control, and with OmniPodâ€™s® convenient auto-cannula insertion, your child never has to see or handle a needle. To learn more and hear from real OmniPod® users, please visit www.MyOmniPod.com. Insulet is delighted to support Friends for Life® Anaheim.
In 1923, the founders of Novo Nordisk began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes. Novo Nordisk is proud to once again be a Platinum Level Sponsor of the Friends for Life® conference, supporting the Family and Friends Banquet and Sports Central. Please come see us at the exhibition to learn more about our type 1 support program, our new camp program and be among the first to learn about the first and only durable insulin pen with 0.5 unit doing and memory function - NovoPen Echo®. To learn more about Novo Nordisk and our support to the Type 1 diabetes community visit us at www.novonordisk-us.com.
Friends of CWD
The American Diabetes Association (Association) is the global authority on diabetes and since 1940 has been committed to its mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To tackle this global public health crisis, the Association drives discovery in research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and provides support and advocacy for people living with diabetes, those at risk of developing diabetes and the health care professionals who serve them. For children with diabetes, the Association serves families as they confront school discrimination issues through our Safe at School initiative. The Association is also the largest single provider of camps for children with diabetes with more than 75 sessions of day and residential camps throughout the nation. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).
Beta Bionics, Inc., is a Massachusetts public benefit corporation committed to innovating, developing, commercializing, and disseminating the iLetÂ®, a dual-hormone bionic pancreas for people living with T1D. Our stated benefit mission is (1) to provide a turnkey solution for safe and effective autonomous glycemic control, (2) to bring this technology to as many people with T1D as possible, (3) to continue to innovate and to offer the latest advances, and (4) to act in the best possible interest of the T1D community. As a benefit corporation founded by parents of children with T1D, Beta Bionics, unlike any other medical technology company, is protected under Massachusetts law to prioritize its benefit mission and place the best interests of the T1D community ahead of all other considerations. Beta Bionics is pleased to be a sponsor of Friends for LifeÂ®. To learn more about Beta Bionics, the iLet, and our public benefit mission, visit us at www.betabionics.org and @BetaBionics on social media.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal. In addition to our research funding and leadership, JDRFâ€™s outreach efforts provide practical support and resources for people with T1D and their families every step of the way as they live with T1D. JDRF is proud to partner with Children with Diabetes by sponsoring regional and national conferences as a charity partner, and supporting sessions at Friends for Life®. For more information, visit the JDRF website at www.jdrf.org, or call 800-533-CURE.
Friends for Life Falls Church 2017 Conference and Expo Introduction - Registration - Sponsors Faculty and Staff - Youth Staff Program - Youth Program - Hotel Floor Plan - Exhibitor Application
|Return to the Top of This Page|
Last Updated: Monday August 28, 2017 14:40:40
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.